- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1534-6269
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma ; volume:19 ; number:2 ; day:28 ; month:2 ; year:2017 ; pages:1-8 ; date:2.2017
Current oncology reports ; 19, Heft 2 (28.2.2017), 1-8, 2.2017
- Keyword
-
Krebs
Onkologie
- Creator
-
Tannir, Nizar M.
- Contributor
-
Schwab, Gisela
Grünwald, Viktor
SpringerLink (Online service)
- DOI
-
10.1007/s11912-017-0566-9
- URN
-
urn:nbn:de:1111-201703306464
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Tannir, Nizar M.
- Schwab, Gisela
- Grünwald, Viktor
- SpringerLink (Online service)
Other Objects (12)
Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports
Population Pharmacokinetics of Cabozantinib in Metastatic Renal Cell Carcinoma Patients: Towards Drug Expenses Saving Regimens
Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma
Population exposure–response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma
Cabozantinib : Cabozantinib in der Behandlung des fortgeschrittenen Nierenzellkarzinoms
Cabozantinib per il trattamento del carcinoma midollare della tiroide
EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma
Correction to: Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use
Identification of genomic drivers for the therapeutic response of Cabozantinib in patients with metastatic renal cell carcinoma
Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma
Final analysis of a noninterventional study on Cabozantinib in patients with advanced renal cell carcinoma after prior checkpoint inhibitor therapy of the German Interdisciplinary Working Group on Renal Tumors (IAG-N)
Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports
Population Pharmacokinetics of Cabozantinib in Metastatic Renal Cell Carcinoma Patients: Towards Drug Expenses Saving Regimens
Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma
Population exposure–response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma
Cabozantinib : Cabozantinib in der Behandlung des fortgeschrittenen Nierenzellkarzinoms
Cabozantinib per il trattamento del carcinoma midollare della tiroide
EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma
Correction to: Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use
Identification of genomic drivers for the therapeutic response of Cabozantinib in patients with metastatic renal cell carcinoma
Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma
Final analysis of a noninterventional study on Cabozantinib in patients with advanced renal cell carcinoma after prior checkpoint inhibitor therapy of the German Interdisciplinary Working Group on Renal Tumors (IAG-N)
Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports
Population Pharmacokinetics of Cabozantinib in Metastatic Renal Cell Carcinoma Patients: Towards Drug Expenses Saving Regimens
Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma
Population exposure–response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma
Cabozantinib : Cabozantinib in der Behandlung des fortgeschrittenen Nierenzellkarzinoms
Cabozantinib per il trattamento del carcinoma midollare della tiroide
EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma
Correction to: Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use
Identification of genomic drivers for the therapeutic response of Cabozantinib in patients with metastatic renal cell carcinoma
Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma